Evaluate the Effects of GPI 1485 on Erectile Function Following Bilateral Nerve-Sparing Prostatectomy
NCT ID: NCT00090376
Last Updated: 2008-11-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
240 participants
INTERVENTIONAL
2003-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
GPI 1485 will be supplied as an oral tablet formulation to men who are candidates for bilateral nerve-sparing prostatectomies. Participants randomly assigned to receive GPI 1485 will be required to take four tablets four times a day by mouth.
GPI 1485 matching placebo will also be supplied as an oral tablet formulation. Participants randomly assigned to placebo will be required to take 4 placebo tablets four times a day by mouth.
Viagra® will be supplied as oral tablets beginning 1 month post-surgery. Patients can begin Viagra® 1 month post-surgery and may continue use until the end of the study, as needed.
The duration of this study is 12 months which includes 5 office visits to your doctor in addition to the surgery day. During this study you will also have other clinical evaluations including a physical exam, blood work, ECG (tracing of your heart rhythm) and urinalysis.
Participants enrolled in this study will also carry a handheld diary that is loaded with special protocol-specific software, which will be referred to as the patient experience diary (PED). Over the duration of this study, participants will complete their questionnaires and answer questions about their medication compliance in the electronic PED.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GPI 1485
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Localized prostate cancer is defined as:
* Gleason score \<=7 (\<=3 + \<=4)
* PSA \<=10 off of finasteride (Proscar®) and dutasteride (Avodart®)
* \<=T2a stage disease
3. Motivated males, 40 to 69 years of age inclusive, and in the opinion of the investigator, are currently in a monogamous, sexually active relationship.
4. Males that have erectile function (EF) (without the use of pharmacotherapy within 30 days prior to screening assessment).
5. EF is defined as a score of \>=26 on the EF domain of the IIEF questionnaire based on patient experiences over the 4 weeks prior to biopsy.
6. Body Mass Index (BMI) within the 18-34.9 kg/m2 range.
7. Able to swallow whole tablets equivalent to capsule size 0.
8. Available for protocol-specified visits and procedures.
9. Informed written consent must be provided prior to any study-specific procedures.
Exclusion Criteria
2. History of peripheral neuropathy.
3. History of acute or chronic depression that in the opinion of the investigator may interfere with protocol-specified efficacy measurements.
4. History of diabetes that requires use of insulin or oral hypoglycemic agents, myocardial infarction, or cerebrovascular accident.
5. History of spinal trauma or surgery to the brain or spinal cord.
6. Any medical disability or laboratory abnormality (e.g., serum creatinine \> 2.0 mg/dL) that, in the opinion of the Investigator, may interfere with the protocol-specified safety and efficacy measurements, present an unacceptable risk to the patient's well-being, or compromise the patient's ability to provide informed consent.
7. History of pelvic radiation therapy (external beam radiation or brachytherapy).
8. Concomitant use of hormonal therapy, vasodilators (nitrates), dutasteride (Avodart®) or finasteride (Proscar®) within the 30 days prior to biopsy and throughout the study.
9. Concomitant use of therapeutic agents to treat ED other than those specified in the protocol is not permitted starting at least 30 days prior to biopsy and continuing throughout the study.
10. Previous exposure to GPI 1485 (previously AMG-474-00).
11. Treatment with an investigational agent within the 30 days before screening or scheduled to receive an investigational agent other than that specified by this protocol during the course of this study.
12. Any contraindication to Viagra® use
13. Unable to stop the use of inducers or inhibitors of cytochrome P450 (CYP) 3A4 from Baseline until the end of the study.
40 Years
69 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Symphony Neuro Development Company
INDUSTRY
Eisai Inc.
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Antonella Favit-Van Pelt, MD, PhD
Role: STUDY_DIRECTOR
Eisai Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
HOPE Research Institute, LLC
Phoenix, Arizona, United States
Center for Urological Research
La Mesa, California, United States
Stanford University Medical Center
Stanford, California, United States
Connecticut Surgical Group
Hartford, Connecticut, United States
Connecticut Urological Research at Grove Hill
New Britain, Connecticut, United States
Tulane University Health Sciences Center
New Orleans, Louisiana, United States
Johns Hopkins Hospital
Baltimore, Maryland, United States
University of Michigan
Ann Arbor, Michigan, United States
Henry Ford Health System, Vattikuti Institute for Urology
Detroit, Michigan, United States
Washington University School of Medicine
St Louis, Missouri, United States
PPS Clinical Research, St. Louis
St Louis, Missouri, United States
Hackensack University Medical Center
Hackensack, New Jersey, United States
NYU Urology Associates
New York, New York, United States
Memorial Sloan-Kettering Cancer Center
New York, New York, United States
Columbia University
New York, New York, United States
Carolinas Health Care System McKay Urology
Charlotte, North Carolina, United States
Duke University Medical Center
Durham, North Carolina, United States
The Cleveland Clinic Foundation
Cleveland, Ohio, United States
Urological Associates of Lancaster, Ltd.
Lancaster, Pennsylvania, United States
Carolina Urologic Research Center
Myrtle Beach, South Carolina, United States
Vanderbilt Medical Center
Nashville, Tennessee, United States
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States
The University of Texas Health Science Center at San Antonio
San Antonio, Texas, United States
Virginia Mason Medical Center
Seattle, Washington, United States
Madigan Army Medical Center
Tacoma, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0501-0202
Identifier Type: -
Identifier Source: org_study_id